Abstract：
Primary salivary gland carcinomas are not among the common head and neck tumors. They are characterized by manifold different histological types. Clinically, malignant tumors often cannot be distinguished from benign tumors, so that in these cases malignancy is only established by histopathological diagnosis. These are all reasons why there are relatively few clinical trials on the diagnosis, therapy and follow-up of these tumors. This in turn has the consequence that often only recommendations with limited evidence can be made in clinical guidelines. The most important international guidelines are the National Comprehensive Cancer Network (NCCN) guideline of 2023, the American Society of Clinical Oncology (ASCO) guideline of 2021, the European Society for Medical Oncology (ESMO) guideline of 2022 and still the British National Multidisciplinary guideline of 2016. These 4 international guidelines with their strengths and limitations are presented and commented here. Against this background, the development of a first German S3 clinical guideline on salivary gland tumors is important and expected to be completed in 2023. For the first time in the German guideline program on oncology, benign and malignant tumors are presented together in order to comprehensively do justice to the special features of salivary gland tumors.
摘要：
原发性唾液腺癌不属于常见的头颈部肿瘤。它们的特征在于各种不同的组织学类型。临床上,恶性肿瘤通常无法与良性肿瘤区分开来，因此，在这些情况下，只有通过组织病理学诊断才能确定恶性肿瘤。这些都是关于诊断的临床试验相对较少的原因，这些肿瘤的治疗和随访。这反过来又导致在临床指南中通常只能提出具有有限证据的建议。最重要的国际指南是2023年的国家综合癌症网络（NCCN）指南，2021年的美国临床肿瘤学会（ASCO）指南，2022年的欧洲医学肿瘤学会（ESMO）指南以及英国国家多学科指南2016年。这里介绍并评论了这4条国际准则及其优点和局限性。在这种背景下,德国首个关于唾液腺肿瘤的S3临床指南的制定非常重要,预计将于2023年完成.这是德国肿瘤学指南计划中的第一次，良性和恶性肿瘤一起提出，以全面公正地对待唾液腺肿瘤的特殊特征。
